Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 10/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007369 | 0.93 | KDR (0.54) | ACKR3KDRNPC1MAPTSIGMAR1 | |
| SCHEMBL16007557 | 0.91 | KDR (0.51) | ACKR3KDRNPC1MAPTRAB9A | |
| SCHEMBL16017715 | 0.90 | DCUN1D1 (0.62) | ACKR3KDM4EMAPTRAB9ADRD4 | |
| SCHEMBL16007807 | 0.89 | ACKR3 (0.53) | ACKR3KDRKDM4ENPC1MAPT | |
| SCHEMBL16007826 | 0.89 | ACKR3 (0.53) | ACKR3KDRKDM4ENPC1MAPT | |
| SCHEMBL16007510 | 0.89 | ACKR3 (0.53) | ACKR3KDRKDM4ENPC1MAPT | |
| SCHEMBL16007606 | 0.88 | KDR (0.53) | ACKR3KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16007512 | 0.87 | SLC6A12 (0.56) | ACKR3KDM4ENPC1MAPTTSHR | |
| SCHEMBL16017739 | 0.86 | KDR (0.52) | ACKR3KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16007186 | 0.85 | KDR (0.54) | KDRNPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | claimed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | claimed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | VEGFA, EDF1, FLT1 | ACKR3 854/4885KDR 4/4885KDM4E 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.